Lack of dissociation of prolactin responses to thyrotropin releasing hormone and metoclopramide in chronic alcoholic men
Tóm tắt
Prolactin, growth hormone and thyroid stimulating hormone responses to thyrotropin releasing hormone (TRH) and metoclopramide were determined in 12 alcoholic men with biopsy proven liver disease and were compared to those of 8 age matched normal controls. All subjects were challenged with TRH (400 μg) and metoclopramide (10 mg) given as an intravenous bolus each on a separate day. Alcoholics had increased basal prolactin and growth hormone levels compared to controls. Alcoholics had a brisk and statistically significant (p < 0.01) response for each of the 3 hormones studied in response to TRH. In contrast to the alcoholics, the controls did not demonstrate a growth hormone response to TRH. Moreover, the TSH response to TRH of the alcoholics was exaggerated (p<0.05) compared to that of the controls. In response to metoclopramide, alcoholics had a brisk prolactin response, failed to demonstrate a TSH response, and had a decline in growth hormone when compared to controls. These results for alcoholics with liver disease differ from those reported for individuals with renal failure while those for the controls are similar to previously reported normal responses. These data suggest that liver disease and renal disease must differ in terms of their patterns of hypothalamic-pituitary neuroregulation as documented by their differing pituitary hormone responses to TRH and metoclopramide.
Tài liệu tham khảo
Feldman H.A., Singer I. Endocrinology and metabolism in uremia and dialysis. Medicine 54: 345, 1974.
McClain C.J., Kromhout J.P., Elson M.K., Van Thiel D.H. Hyperprolactinemia in portal systemic encephalopathy. Dig. Dis. Sci. 26: 353, 1981.
Van Thiel D.H., Smith V.I. Jr., McClain C.J., Lester R. Abnormal prolactin and growth hormone response to thyrotropin releasing hormone in chronic alcoholic men. Curr. Alcohol. 5: 71, 1979.
Ramirez G., O’Neill W.M., Bloomer H.A., Jubiz W. Abnormalities in the regulation of prolactin in patients with chronic renal failure. J. Clin Endocrinol. Metab. 45: 658, 1977.
Lim V.S., Kuthpalia S.C., Frohman L.A. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J. Clin. Endocrinol. Metab. 48: 101, 1979.
Sowers J.R., McCallum R.W., Hershman J.M., Carlson H.E., Sturdevant R.A.L., Meyer N. Comparison of metoclopramide with other dynamic tests of prolactin secretion. J. Clin. Endocrinol. Metab. 43: 679, 1976.
Leroith D., Damovitz G., Trestan S., Spitz I.M. Dissociation of prolactin response to thyrotropin releasing hormone and metoclopramide in chronic renal failure. J. Clin. Endocrinol. Metab. 49: 815, 1979.
Panerai A.E., Salerno F., Manneschi M., Cocchi D., Müller E.E. Growth hormone and prolactin responses to thyrotropin releasing hormone in patients with severe liver disease. J. Clin. Endocrinol. Metab. 45: 134, 1977.
Zanoboni A., Zanoboni-Muciaccia W. Elevated basal growth hormone levels and growth hormone responses to TRH in alcoholic patients with cirrhosis. J. Clin. Endocrinol. Metab. 45: 576, 1977.
Van Thiel D.H., Gavaler J.S., Wight C., Smith W.I. Jr., Abuid J. Thyprotopin releasing hormone (TRH)-induced growth hormone (hGH) responses in cirrhotic men. Gastroenterology 75: 66, 1978.
Van Thiel D.H., Smith W.I. Jr., McClain C.J., Lester R. Abnormal prolactin and growth hormone responses to thyrotropin releasing hormone in chronic alcoholic men. In: Galanter M. (Ed.), Currents in alcoholism VIII. Grune & Stratton, Inc., New York, 1979, p. 71.
Bassiri R.M., Utiger R.D. Metabolism and execution of exogenous thyrotropin releasing hormone in humans. J.Clin. Invest. 52: 1616, 1973.
Phillips G.B., Schwartz R., Gabuzda G.J., Davidson C.S. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. N. Engl. J. Med. 247: 239, 1952.
Havens L.L., Child G.G., III. Recurrent psychosis associated with liver disease and elevated blood ammonia. N. Engl. J. Med. 252: 756, 1954.
Webster L.T., Jr., Gabuzda G.J. Relation of azotemia to blood ammonium in patients with hepatic cirrhosis. Arch. Intern. Med. 103: 15, 1959.
McDermott W.V. Jr. Diversion of urine to the intestines as a factor in ammoniogenic coma. N. Engl. J. Med. 256: 460, 1957.
Mortensen E., Lyng G., Juhl E. Ammonia induced coma after ureterosigmoidostomy. Lancet 1: 496, 1972.
Muting D. Studies on the pathogenesis of uremia. Clin. Chim. Acta 12: 551, 1965.
Harrison T.R., Mason M.F. The pathogenesis of the uremic syndrome. Medicine 16: 1, 1937.
Dickes R., Relations between the symptoms of uremia and the blood levels of the phenols. Arch. Intern. Med. 69: 446, 1942.
Bessman S.P., Fazekas J.F., Bessman A.N. Uptake of ammonia by the brain in hepatic coma. Proc. Soc. Exp. Biol. Med. 85: 66, 1954.
Baldessarini R.J., Yonke C. Uptake and release of possible false neurotransmitters amino acids by rat brain tissue. J. Neurochem. 24: 839, 1974.
Fischer J.E., Baldessarini R.J. False neurotransmitter and hepatic failure. Lancet 2: 75, 1971.
Ogihara K., Mozai T., Hirai S. Tryptrophan as a cause of hepatic coma. N. Engl. J. Med. 275: 1255, 1966.
Foley J.M., Watson C.W., Adams R.D. Significance of the electroencephalographic changes in hepatic coma. Trans. Am. Neurol. Assoc. 75: 161, 1950.
Summerskill W.H.J., Wolfe S.J., Davidson C.S. The management of hepatic coma in relation to protein withdrawal and certain specific measures. Am.J. Med. 23: 59, 1957.
Greenberger N.J., Carley J., Schenker S., Bettinger I., Stammer C., Beyer P. Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Am. J. Dig. Dis. 22: 845, 1977.
Fischer J.E., James J.H. Treatment of hepatic coma and hepatic renal syndrome: mechanism of action of L-dopa and aramine. Am. J. Surg. 123: 222, 1972.
Parkers J.D., Sharpstone R., Williams R. Levodopa in hepatic coma. Lancet 2: 1341, 1979.
Posado J.G., Penicha J.H., Tirado-Arroyava S. Effect of 3–4 dihydroxyphenlalanine (L-dopa) in hepatic coma. Arch. Invest. Med. 3: 1, 1972.
Uribe M., Farca R., Marquez M.A., Garcia-Ramos G., Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine. Gastroenterology 76: 1333, 1979.
Morgan M.Y., Jakobovits A.W., James I.M., Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78: 663, 1980.
Michael H., Solere M., Geranier P., Cavet G., Bali J.P., Pons F., Bellet-Herman H. Treatment of cirrhotic hepatic encephalopathy with L-dopa a controlled trial. Gastroenterology 79: 209, 1980.